Protalix Biotherapeutics, Inc. (PLX) fundamentals score
Protalix Biotherapeutics is a commercial stage biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs. It is the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NYSE
Overall: 7.2 out of 10, Mixed fundamentals
- Growth: 6.3/10
- Profitability: 8.6/10
- Financial health: 9.4/10
- Earnings quality: 4.1/10
- Valuation: 6.7/10
Scores are calculated from Protalix Biotherapeutics, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10